Aspire Biopharma, Inc. (NASDAQ:PWUP)

PRESS RELEASE

published on 06/10/2025 at 14:30, 8 months 10 days ago

Aspire Biopharma Holdings, Inc., Announces Michael C. Howe - With Decades of Experience at Leading and Building Brands in the Healthcare and Consumer Space - To Be Its New Chief Executive Officer
Michael Howe to become CEO of Aspire Biopharma Holdings, Inc. on June 10, 2025. His extensive career in leading brands and early-stage companies makes him a strategic fit for the role

Healthcare Board Member CEO Michael Howe Aspire Biopharma Holdings, Inc.
BRIEF

published on 05/28/2025 at 14:35, 8 months 23 days ago

Aspire Biopharma dévoile BUZZ BOMB™ : une nouvelle ère dans les compléments pré-entraînement

Technologie Sublinguale Marché Du Fitness Supplément Pré-entraînement BUZZ BOMB™ Livraison De Caféine
BRIEF

published on 05/28/2025 at 14:35, 8 months 23 days ago

Aspire Biopharma Unveils BUZZ BOMB™: A New Era in Pre-Workout Supplements

Sublingual Technology Fitness Market Pre-workout Supplement BUZZ BOMB™ Caffeine Delivery
PRESS RELEASE

published on 05/28/2025 at 14:30, 8 months 23 days ago

Aspire Biopharma Holdings, Inc., Provides Development Update on BUZZ BOMB(TM), its New Sublingual Pre-Workout Supplement, Expected to Launch in Third Quarter of 2025
Aspire Biopharma introduces BUZZ BOMB™, a sublingual pre-workout supplement delivering rapid caffeine to support athletes' performance. Six flavors available in convenient single servings. Global pre-workout supplements market on the rise

Aspire Biopharma Pre-workout Supplement Sublingual BUZZ BOMB™ Caffeine
BRIEF

published on 05/20/2025 at 14:35, 9 months ago

Aspire Biopharma lance un essai de phase 1 sur une formulation d'aspirine à haute dose

Développement Clinique Examen De La FDA Essai De Phase 1 Aspirine À Haute Dose Absorption Sublinguale
BRIEF

published on 05/20/2025 at 14:35, 9 months ago

Aspire Biopharma Begins Phase 1 Trial of High-Dose Aspirin Formulation

Clinical Development Phase 1 Trial FDA Review High-dose Aspirin Sublingual Absorption
PRESS RELEASE

published on 05/20/2025 at 14:30, 9 months ago

Aspire Biopharma Holdings, Inc., Announces First Patient Dosed in Phase 1 Clinical Trial for its Lead Program, an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
Aspire Biopharma initiates Phase 1 trial for high-dose aspirin formulation in the United States, targeting accelerated approval with positive data anticipated in 3Q 2025

Accelerated Approval Phase 1 Trial FDA Feedback Aspire Biopharma High-dose Aspirin Formulation
BRIEF

published on 05/08/2025 at 14:05, 9 months 12 days ago

Aspire Biopharma to Participate in Sidoti Virtual Investor Conference

Investor Presentation Drug Delivery Technology Sidoti Conference Aspire Biopharma Virtual Meetings
BRIEF

published on 05/08/2025 at 14:05, 9 months 12 days ago

Aspire Biopharma participera à la conférence virtuelle des investisseurs de Sidoti

Presentation Aux Investisseurs Technologie D'administration De Médicaments Conférence De Sidoti Aspire Biopharma Réunions Virtuelles
PRESS RELEASE

published on 05/08/2025 at 14:00, 9 months 12 days ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference May 21
Aspire Biopharma to present at Sidoti Virtual Investor Conference on May 21 and host virtual one-on-ones with investors. Company's disruptive drug delivery technology highlighted

Sidoti Virtual Investor Conference Virtual Presentation One-on-one Meetings Drug Delivery Technology Aspire Biopharma

Published on 02/20/2026 at 20:15, 16 minutes ago

Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 16 minutes ago

Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 2 hours 1 minute ago

Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 4 hours 46 minutes ago

Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 6 hours 1 minute ago

Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant

View all ACCESSWIRE

Published on 02/20/2026 at 18:36, 1 hour 55 minutes ago

EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 2 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:23, 2 hours 8 minutes ago

POS-Transaction in Own Shares
Published on 02/20/2026 at 18:00, 2 hours 31 minutes ago

Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 2 hours 31 minutes ago

Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations

View all EQS

Published on 02/20/2026 at 19:29, 1 hour 2 minutes ago

SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 1 hour 2 minutes ago

SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 2 hours 31 minutes ago

TERACT - Termination of liquidity agreement
Published on 02/20/2026 at 18:00, 2 hours 31 minutes ago

TERACT - Résiliation du contrat de liquidité
Published on 02/20/2026 at 17:35, 2 hours 56 minutes ago

CHIFFRE D'AFFAIRES 2025

View all LES ECHOS COMFI WIRE

News